GIMEMA CLL0809 Study (BendOfa)

NCT01244451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or
Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines

Interventions

DRUG: Ofatumumab
DRUG: Bendamustine

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto